Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $2.5 million.

  • Ernexa Therapeutics' Total Non-Current Liabilities fell 9530.81% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 9530.81%. This contributed to the annual value of $3.5 million for FY2024, which is 9261.06% down from last year.
  • According to the latest figures from Q3 2025, Ernexa Therapeutics' Total Non-Current Liabilities is $2.5 million, which was down 9530.81% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Ernexa Therapeutics' Total Non-Current Liabilities registered a high of $54.9 million during Q2 2024, and its lowest value of $2.5 million during Q3 2025.
  • In the last 5 years, Ernexa Therapeutics' Total Non-Current Liabilities had a median value of $10.0 million in 2021 and averaged $21.3 million.
  • Per our database at Business Quant, Ernexa Therapeutics' Total Non-Current Liabilities surged by 61930.09% in 2024 and then plummeted by 9530.81% in 2025.
  • Over the past 5 years, Ernexa Therapeutics' Total Non-Current Liabilities (Quarter) stood at $7.0 million in 2021, then soared by 40.7% to $9.8 million in 2022, then skyrocketed by 375.39% to $46.8 million in 2023, then plummeted by 92.61% to $3.5 million in 2024, then dropped by 27.97% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $3.0 million for Q2 2025, and $10.9 million during Q1 2025.